Literature DB >> 9566852

The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin.

L Berti1, M Kellerer, B Bossenmaier, E Seffer, G Seipke, H U Häring.   

Abstract

HOE 901 is a new biosynthetic long-acting human insulin analog (GLY[A21]ARG[B31]ARG[B32]). We compared HOE 901 with normal human insulin and the insulin analog Asp(B10), which is known to have increased mitogenic activity at least partially mediated through the insulin receptor. We have analyzed receptor binding, insulin-induced receptor autophosphorylation and phosphorylation of receptor substrates in rat-1 fibroblasts overexpressing human insulin receptor isoform A (HIR A) or B (HIR B). In HIR A expressing cells, insulin and its analogs showed no significant differences in receptor association while clearly different dissociation kinetics were observed. In HIR B expressing cells, no significant differences in association and dissociation kinetics were observed. All insulins induced rapid autophosphorylation of the insulin receptor reaching a maximum after 10 min of stimulation. Asp(B10)insulin induced a prolonged phosphorylation state (over 60 minutes) of the 95 kDa receptor beta-subunit and of the substrates IRS-1/IRS-2 and Shc in contrast to normal human insulin and to HOE 901. In addition, we observed an increased and prolonged tyrosine phosphorylation of an unidentified protein with Asp(B10)insulin at about 60 kDa. Insulin-dependent dephosphorylation of the focal adhesion kinase (p125FAK) was equally induced by all these ligands. With respect to [3H]thymidine incorporation into DNA, HOE 901 had similar effects as normal human insulin, while Asp(B10)insulin showed increased [3H]thymidine incorporation. In summary, the data show that the increased mitogenic activity of Asp(B10)insulin may be explained with a prolonged kinetics of tyrosine phosphorylation of the insulin receptor and of insulin signalling elements together with the preferential phosphorylation of an yet unidentified 60 kDa protein. HOE 901 behaves with respect to insulin receptor binding, receptor autophosphorylation, phosphorylation of signalling elements and promotion of mitogenesis like regular human insulin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9566852     DOI: 10.1055/s-2007-978849

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  21 in total

1.  Effects of new insulin analogues HMR1964 (insulin glulisine) and HMR1423 on insulin receptors.

Authors:  A M Hennige; V Strack; E Metzinger; G Seipke; H-U Häring; M Kellerer
Journal:  Diabetologia       Date:  2005-07-29       Impact factor: 10.122

2.  Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling.

Authors:  L Sciacca; M F Cassarino; M Genua; G Pandini; R Le Moli; S Squatrito; R Vigneri
Journal:  Diabetologia       Date:  2010-04-28       Impact factor: 10.122

3.  Differences in bioactivity between human insulin and insulin analogues approved for therapeutic use- compilation of reports from the past 20 years.

Authors:  Haim Werner; Ernst A Chantelau
Journal:  Diabetol Metab Syndr       Date:  2011-06-29       Impact factor: 3.320

4.  Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor.

Authors:  E Yehezkel; D Weinstein; M Simon; R Sarfstein; Z Laron; H Werner
Journal:  Diabetologia       Date:  2010-09-12       Impact factor: 10.122

Review 5.  Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus.

Authors:  K McKeage; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 6.  New aspects of insulin therapy in type 1 and type 2 diabetes.

Authors:  D G Dills
Journal:  Curr Diab Rep       Date:  2001-10       Impact factor: 4.810

7.  Design of an insulin analog with enhanced receptor binding selectivity: rationale, structure, and therapeutic implications.

Authors:  Ming Zhao; Zhu-li Wan; Linda Whittaker; Bin Xu; Nelson B Phillips; Panayotis G Katsoyannis; Faramarz Ismail-Beigi; Jonathan Whittaker; Michael A Weiss
Journal:  J Biol Chem       Date:  2009-09-22       Impact factor: 5.157

8.  IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts.

Authors:  K Eckardt; C May; M Koenen; J Eckel
Journal:  Diabetologia       Date:  2007-09-18       Impact factor: 10.122

Review 9.  Insulin glargine: an updated review of its use in the management of diabetes mellitus.

Authors:  Christopher J Dunn; Greg L Plosker; Gillian M Keating; Kate McKeage; Lesley J Scott
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Synchronization in G0/G1 enhances the mitogenic response of cells overexpressing the human insulin receptor A isoform to insulin.

Authors:  Christine Bonnesen; Gitte-Mai Nelander; Bo Falck Hansen; Pia Jensen; Jonas S Krabbe; Marianne B Jensen; Anne Charlotte Hegelund; Jette E Svendsen; Martin B Oleksiewicz
Journal:  Cell Biol Toxicol       Date:  2009-11-08       Impact factor: 6.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.